

DRUG INFORMATION

JOURNAL

Official Publication of the
Drug Information Association



PERGAMON PRESS New York • Oxford • Beijing • Frankfurt • São Paulo
Sydney • Tokyo • Toronto

DRUG INFORMATION JOURNAL

Official Publication of the Drug Information Association

EDITOR-IN-CHIEF

Thomas W. Teal

Administrative Director, Drug Information Association

EDITORIAL BOARD

Term ends December 31, 1986

George A. Braun, PhD, *Johnson & Johnson*
Vera C. Glocklin, PhD, *U.S. Food and Drug Administration*
Raymond H. Kahn, PhD, *Scripps Clinic and Research Foundation*
Louise S. Kaufman, PhD, *Merck & Company*
Gary G. Koch, PhD, *University of North Carolina*
Steven R. Moore, MPH, *U.S. Food and Drug Administration*
Stephen W. Schondelmeyer, PharmD, PhD, *Purdue University*
Michael J. Zelesko, PhD, *McNeil Pharmaceutical*

Term ends December 31, 1987

Joseph R. Assenzo, PhD, *The Upjohn Company*
Allen Cato, MD, PhD, *Burroughs Wellcome*
Donald P. Cox, PhD, *Janssen Pharmaceutica*
Robert V. Cuddihy, *Oxford Research International*
Melvin P. Fisher, PhD, *McNeil Pharmaceutical*
Michael L. Grozier, MD, *Pennwalt Pharmaceutical Division*
Craig Hammes, Esq, *McNeil Consumer Products*
Raymond L. Herman, MA, *Stuart Pharmaceutical*
Daniel Hussar, PhD, *Philadelphia College of Pharmacy & Science*

Editorial Office: Editor-in-Chief, *Drug Information Journal*, P.O. Box 113, Maple Glen, PA 19002, USA.

Publishing, Subscription, and Advertising Offices: Pergamon Journals Inc., Fairview Park, Elmsford, NY 10523, USA; or Pergamon Journals Ltd., Headington Hill Hall, Oxford OX3 0BW, England.

Published Quarterly: Annual subscription rate (1986): US\$80.00; Two-year rate (1986/87): US\$152.00. Back issue and microform subscription information available upon request. All prices include surface postage and insurance. Prices subject to change without notice.

Drug Information Association members receive the *Drug Information Journal* as part of their annual dues. The association is dedicated to the extension of modern technology in biomedical information and data processing as well as the encouragement of cooperative efforts among education, research, industrial, and government personnel to disseminate information of that type. For information concerning membership, please see the Membership Information Page elsewhere in this issue, or write to: Drug Information Association, P.O. Box 113, Maple Glen, PA 19002.

Copyright © 1986 Drug Information Association Inc.

Printed in the USA

Copyright Notice: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electric, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A.: The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of \$3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

Permission for other use. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. Please contact the Subsidiary Rights Manager, Publishing Services Dept. at either Pergamon Journals Ltd. or Pergamon Journals Inc.

The Item-Fee Code for this publication is: 0092-8615/86 \$3.00 + .00

Contents Volume 20, 1986

Volume 20, Number 1

1986

CONTENTS

- | | | |
|--|----|--|
| Thomas W. Teal | 1 | Editor's Note |
| Thomas W. Teal | 5 | Editor's Note |
| Charles C. Leighton | 7 | Clinical Data Processing in Retrospect and in Prospect |
| Robert W. Deller | 17 | Proposed Methodologies for Reviewing Clinical Data by Remote Access |
| Richard N. Spivey A. Gene Trimble | 27 | Effect of the Drug Price Competition Act on Market Exclusivity of New Drugs: A Simulation |
| Robert J. Bronstein | 37 | The Concept of a Validation Plan |
| Lars S. Palmer | 43 | Computing in a Pharmaceutical Company: Hässle's Unconventional Approach |
| Theodore Legatt Alan Saltzman | 51 | Development of a Chemical Structure Display System and its Interface with the Associated Biological Database |
| Ildiko D. Trombitas Rolly L. Simpson, Jr | 57 | Monitoring the World's Published Literature for Adverse Drug Experiences |
| Dennis F. Thompson Mary Lee | 63 | Online Medline Plus Fan Search V Offsearch: A Comparison of Literature Retrieval Methods |
| Duane M. Kirking Christopher J. Maksym Patricia D. Neterer Frank J. Ascione Carol L. Colvin | 69 | Evaluation of Questions Received by Community Pharmacists |
| R. Dewayne Caldwell Joyce A. Generali Bruce E. Scott Sara J. White Kenneth Gerald | 77 | Comparison of Drug Information Resources Observed in Community Pharmacies: Chain Versus Independent |

- | | | |
|---|-----|---|
| Dennis Black Kjeld Molvig Anna Bagniewska Stan Edlavitch Cary Fox Stephen Hulley W. McFate Smith | 83 | A Distributed Data Processing System for a Multicenter Clinical Trial |
| Khalid A. Madani Hamza Al-Abbasi | 93 | Drug Administration in Saudi Arabia |
| Mary G. Royer | 97 | Preparing Manuscripts for Publication: A Team Approach |
| George C. S. Yu | 103 | Remote Data Entry and Retrieval: The Human and Administrative Aspects |
| Marshall C. Tate Lee Wanke Philip Blume Norman Muilenburg | 109 | Storage and Retrieval of Data from Drug Information Requests Using a Mumps-Based Information System |

CONTENTS

- | | | |
|--|-----|---|
| Robert Z. Gussin | 115 | Recent Developments in Biotechnology: The Influence on Drug Development |
| Elizabeth E. Force | 121 | System for Currency of Adverse Effects in Package Circulars |
| Robert Temple | 127 | Effective Design of Clinical Studies |
| Mary B. Forbes Anastasia E. Perez Alan Gelberg | 135 | FDA's Adverse Drug Reaction Drug Dictionary and its Role in Post-Marketing Surveillance |
| Wayne M. Turner Julie B. Milstien Gerald A. Faich George D. Armstrong | 147 | The Processing of Adverse Reaction Reports at FDA |
| Judith M. Sills Gerald A. Faich Julie B. Milstien Wayne M. Turner | 151 | Postmarketing Reporting of Adverse Drug Reactions to the FDA: An Overview of the 1985 FDA Guideline |

- Julie B. Milstien** 157 Factors Affecting Physician Reporting of Adverse Drug Reactions
Gerald A. Faich
J. P. Hsu
Deanne E. Knapp
Carlene Baum
Michael W. Dreis
- Lawrence G. Bassin** 165 Functioning of a Medical Information Unit within a Large Pharmaceutical Organization: A Methodological Approach and Review
Pamela A. Bilhuber
- Ann B. Amerson** 173 Drug Information Centers: An Overview
- Irvin Strathman** 179 Experience with the WHO Adverse Reaction Terminology at Searle
- Fred J. Salter** 187 Management of Drug Information Inquiries from Health Care Professionals: An Industry-Wide Survey
James C. Kawano
David A. Pherson
- Thomas J. Ott** 195 Clinical Quality Assurance
Stephen A. Herczeg
Robert K. Campbell
- Daniel E. Klinger** 199 Drug Safety Evaluation Automation: A Distributed System Approach
G. James Davies
- Robert A. Weeks** 213 A SAS Based System for Reporting Laboratory Data from Clinical Trials
Norman E. Pitts
Andrew M. Siegel
Lonni A. Zubkoff
David I. Hopp
- A. Mari-Ann Wallander** 225 A Monitoring System for Adverse Drug Experiences in a Pharmaceutical Company: The Integration of Pre- and Postmarketing Data
Lars S. Palmer
- Roberto Gomeni** 237 CLINIC/3000: A New Approach for Clinical Database Implementation and Management
Yen Nga La
Nicolas Issakides
Marc Antoine de Rotrou
- I Software Survey Section: *NUMBER CRUNCHER STATISTICAL SYSTEM*
-

Special Issue: Clinical Data Management

CONTENTS

- L. S. Kaufman** 255 Foreword and Acknowledgements
- Edmund W. J. de Maar** 257 The Global Core Clinical Protocol and Its Rational Adaptations
- Stuart J. Pocock** 263 Interim Analyses in Randomized Clinical Trials
Nancy L. Geller
- Ruth A. Young** 271 A Remote Data Entry System for International Clinical Trials
- Anthony D'Ambrosio** 275 An Interactive Clinical Monitoring System
- Gene Sogliero-Gilbert** 279 A Procedure for the Simplification and Assessment of Lab Parameters in Clinical Trials
Ken Mosher
Lonni Zubkoff
- John C. C. Talbot** 297 Management of ADR Data from Different Sources
- S. M. Streichenwein** 301 Actual Aspects of Data Integration—A View from an International Company
- David I. Goldsmith** 305 A Comprehensive System for International Pharmaceutical Company Monitoring of Adverse Drug Reactions
Chialing C. Yen
Bruce P. Greenberg
- K. Abt** 311 Pooling of Laboratory Safety Data in Multicenter Studies
P. Krupp
- Robert A. Michalak** 315 PANACEA and the Blue Patients
- J. F. Dunne** 319 The CIOMS/WHO Project on the Assessment of Adverse Drug Effects
- W. M. Castle** 323 Problems in Assessing Drug Safety: A Plea for Improved Methodology and a Possible Route
- Myles D. B. Stephens** 327 Assessment of Adverse Event Data in Large-Scale Clinical Trials
- J. Dangoumau** 337 A Drug Information-ADR Collection Network: The French System
G. Lagier
R. J. Royer
- M. Girard** 347 Post-Marketing Surveillance: An Art or a Science?

- Raymond L. Herman** 351 System Integration of an Adverse Experience Thesaurus—Experience with a New Computer Methodology
- R. Grohmann** 357 Reliability of Adverse Drug Reaction Assessment in Psychiatric Inpatients
P. Dirschedl
J. Scherer
L. G. Schmidt
O. Wunderlich
- Duilio Poggiolini** 363 Drug Registration in Europe and the EEC
- C. A. Teijgeler** 367 The Committee for Proprietary Medicinal Products (CPMP)—Past History and Future Changes
- G. Jones** 373 U.K. Applications Submitted to the CPMP
- Bernhard Schnieders** 377 Evaluation Report of the CPMP
- I Software Survey Section: *ACES (Automated Clinical Evaluation System); ChemBase*

 Volume 20, Number 4

1986

Special Issue: The Future of Adverse Drug Reaction Diagnosis:
Computers, Clinical Judgement and Logic of Uncertainty

CONTENTS

- Judith K. Jones** 383 Introduction and Foreword
Raymond L. Herman
- 385 DIA Workshop on Causality Assessment Address List of Participants
- AN INTRODUCTION TO CAUSALITY ASSESSMENT—WHO, WHAT, AND WHY*
- Claudio A. Naranjo** 387 A Clinical Pharmacologic Perspective on the Detection and Assessment of Adverse Drug Reactions
- J. Richard Crout** 395 Introduction to Causality Assessment—Who, What and Why? The Manufacturer's Perspective
- William B. Freilich** 399 The Legal Perspective

- Bernard Begaud** 409 The Regulatory Perspective
Rene Jean Royer

- Judith K. Jones** 413 Epidemiologic Perspective on Causality Assessment
for Drug Associated Events

*THE DIFFICULTIES OF CAUSALITY
ASSESSMENT*

- Jan Venulet** 423 Incomplete Information as a Limiting Factor in
Causality Assessment of Adverse Drug Reactions
and Its Practical Consequences

STRATEGIES FOR ASSESSING CAUSALITY

- Michael S. Kramer** 433 Assessing Causality of Adverse Drug Reactions:
Global Introspection and Its Limitations

- Tom A. Hutchinson** 439 Standardized Assessment Methods for Adverse
Drug Reactions: A Review of Previous Approaches
and Their Problems

*TOWARDS A NEW APPROACH TO
CAUSALITY ASSESSMENT*

- David A. Lane** 445 The Logic of Uncertainty: Measuring Degree of Belief

*A NEW APPROACH TO ADVERSE
REACTION CAUSALITY ASSESSMENT*

- David A. Lane** 455 The Bayesian Approach to Causality Assessment:
An Introduction

APPLICATIONS OF THE NEW APPROACH

- 463 Analysis of Clinical Cases—Preamble

- Claudio A. Naranjo** 465 A Bayesian Approach to Assessment of Adverse
Drug Reactions: Evaluation of a Case of Cholestatic
Jaundice

- Claudio A. Naranjo** 473 Discussion Panel: Model 1—Cholestatic Jaundice

- Tom A. Hutchinson** 475 A Bayesian Approach to Assessment of Adverse
Drug Reactions: Evaluations of a Case of Acute
Renal Failure

- Tom Hutchinson** 483 Discussion Panel: Model 2—Acute Renal Failure

- Judith K. Jones** 487 Evaluation of a Case of Stevens-Johnson Syndrome

- Judith K. Jones** 503 Discussion Panel: Model 3—Stevens-Johnson Syndrome
- Michael S. Kramer** 505 A Bayesian Approach to Assessment of Adverse Drug Reactions: Evaluation of a Case of Fatal Anaphylaxis
- Michael S. Kramer** 519 Discussion Panel: Model 4—Anaphylaxis
- Michael S. Kramer** 523 A Bayesian Approach to Causality Assessment for Adverse Drug Reactions: Analysis of a Case of Exfoliative Dermatitis
- Tom A. Hutchinson**
David A. Lane
Judith K. Jones
Claudio A. Naranjo
- Edward Sellers** 535 Discussion on How and When Can This Approach Be Applied and Initial Reactions

*THE FUTURE OF CAUSALITY
ASSESSMENT*

- David J. Spiegelhalter** 543 Computers, Expert Systems, and ADRs: Can Causality Assessment be Automated?
- Judith K. Jones** 551 Discussion Panel: The Future of Causality Assessment: Is It Wise? Will It Help? What Effect Could It have On the Analysis of Clinical Trial Data or in Pharmacoepidemiology?

563 Selected References

569 Index to Volume 20, 1986

I Software Survey Section

FELLOWSHIP FOR MEDICAL LIBRARIANS

The Medical Library Association (MLA), an organization of 5,000 medical librarians and libraries, is offering the Cunningham Memorial International Fellowship, a six-month fellowship for medical librarians from outside the United States or Canada. The six-month fellowship provides a medical librarian with an opportunity for observation and supervised work in one or more libraries in the United States or Canada during the period from December 1987 to June 1988.

The Fellowship provides a stipend of \$3,000 toward living expenses and \$500 for travel expenses within the United States and Canada. Travel arrangements to and from the United States or Canada must be paid for by the fellow.

Candidates for the six-month program must have an undergraduate degree and a library degree (the latter requirement may be waived). They must be working in a medical library or preparing to work in one in their own countries and must agree, when accepting the Fellowship, to return home to work in a medical library for a period of two years. (The candidate must have a signed statement by a responsible official of the institution where he or she is working or plans to work, guaranteeing a position in a medical library when he or she returns.) An applicant whose native language is not English must present evidence of having passed the TOEFL examination with a score of 600 or above.

Additional information and application forms may be obtained from Professional Development Department, Medical Library Association, 919 N. Michigan Avenue, Chicago, IL 60611, U.S.A. Completed applications and all supporting credentials must be received by *February 1, 1987*.

VOL
20
198

Author Index Volume 20, 1986

- Abt K, 311
 Al-Abbasi H, 93
 Amerson AB, 173
 Armstrong GD, 147
 Ascione FJ, 69

 Bagniewska A, 83
 Bassin LG, 165
 Baum C, 157
 Begaud B, 409
 Bilhuber PA, 165
 Black D, 83
 Blume P, 109
 Bronstein RJ, 37

 Caldwell RD, 77
 Campbell RK, 195
 Castle WM, 323
 Colvin CL, 69
 Crout JR, 395

 D'Ambrosio A, 275
 Dangoumanu J, 337
 Davies GJ, 199
 deMarr EWJ, 257
 de Rotrou M, 237
 Deller RW, 17
 Dirschedl P, 357
 Dreis MW, 157
 Dunne JF, 319

 Edlavitch S, 83

 Faich GA, 147, 151, 157

 Forbes MB, 135
 Force EE, 121
 Fox C, 83
 Freilich WB, 399

 Gelberg A, 135
 Geller NL, 263
 Generali JA, 77
 Gerald K, 77
 Girard M, 347
 Goldsmith DI, 305
 Gomeni R, 237
 Greenberg BP, 305
 Grohmann R, 357
 Gussin RZ, 115

 Herczeg SA, 195
 Herman RL, 351, 383
 Hopp DI, 213
 Hsu JP, 157
 Hulley S, 83
 Hutchinson T, 483
 Hutchinson TA, 439, 475, 523

 Issakides N, 237

 Jones G, 373
 Jones JK, 383, 413, 487, 503, 523, 551

 Kaufman LS, 255
 Kawano JC, 187
 Kirking DM, 69

 Klinger DE, 199
 Knapp DE, 157
 Kramer MS, 433, 505, 519, 523
 Krupp P, 311

 La YN, 237
 Lagier G, 337
 Lane DA, 445, 455, 523
 Lee M, 63
 Legatt T, 51
 Leighton CC, 7

 Madani KA, 93
 Maksym CJ, 69
 Michalak RA, 315
 Milstien JB, 147, 151, 157
 Molvig K, 83
 Mosher K, 279
 Muilenburg N, 109

 Naranjo CA, 387, 465, 473, 523
 Neterer PD, 69

 Ott TJ, 195

 Palmer LS, 43, 225
 Perez AE, 135
 Pherson DA, 187
 Pitts NE, 213
 Pocock SJ, 263
 Poggiolini D, 363

 Royer MG, 97

- Royer RJ, 337, 409
- Salter FJ, 187
- Saltzman A, 51
- Scherer J, 357
- Schmidt LG, 357
- Schnieders B, 377
- Scott BE, 77
- Sellers E, 535
- Siegel AM, 213
- Sills JM, 151
- Simpson RL, Jr, 57
- Smith WM, 83
- Sogliero-Gilbert
G, 279
- Spiegelhalter DJ,
543
- Spivey RN, 27
- Stephens MDB,
327
- Strathman I, 179
- Streichenwein
SM, 301
- Talbot JCC, 279
- Tate MC, 109
- Teal TW, 1, 5
- Teijgeler CA, 367
- Temple R, 127
- Thompson DF, 63
- Trimble AG, 27
- Trombitas ID, 57
- Turner WM, 147,
151
- Venulet J, 423
- Wallander AM,
225
- Wanke L, 109
- Weeks RA, 213
- White SJ, 77
- Wunderlich O,
357
- Yen CC, 305
- Young RA, 271
- Yu GCS, 103
- Zubkoff L, 279
- Zubkoff LA, 213

L.
O
86